Day301
-
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Congratulations to Day One Biopharmaceuticals and MabCare Therapeutics!